Current Understanding of PDE10A in the Modulation of Basal Ganglia Circuitry
Jan-Philip Schülke1, Nicholas J Brandon2
1Evotec, Am Klopferspitz 19a, 82152, Martinsried, Germany. Jan-Philip.Schuelke@evotec.com.
Abstract:
The basal ganglia are a forebrain network of interconnected nuclei that are involved in action selection, reward circuits and coordinating movement. PDE10A inhibition has been proposed as a novel way to modulate basal ganglia circuitry and to ameliorate symptoms in Huntington's disease, Parkinson's disease and Schizophrenia. However, despite encouraging results from pre-clinical models, PDE10A inhibitors failed to show efficacy as an antipsychotic in several clinical trials. PDE10A is expressed in the medium spiny neurons of the striatum and works to limit cyclic nucleotide signaling in response to modulatory neurotransmitters like dopamine. In this chapter, we will review the current literature on PDE10A and discuss how inhibition of PDE10A will result in alterations of the basal ganglia circuitry at the biochemical, physiological and behavioral level.
Related Concept Videos
Neural Regulation
Parkinson's Disease: Overview
Postsynaptic Potential (PSP)
There are two types of receptors: ionotropic and metabotropic.
The ionotropic receptor is the membrane protein that has an...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...


